RESUMEN
A simple, fast and high-throughput LC-tandem mass spectrometry method was developed and validated to simultaneously measure liraglutide and insulin degludec in rat plasma. After protein precipitation, plasma samples were subjected to gradient elution using an InertSustain Bio C18 column with 1000/20/1 water/acetonitrile/formic acid (v/v/v) and 1000/1 acetonitrile/formic acid (v/v) as the mobile phase. The method was validated from 1.00 to 500 ng/mL of liraglutide and insulin degludec. Further, the extraction recovery from the plasma was 41.8%-49.2% for liraglutide and 56.5%-69.7% for insulin degludec. Intra- and inter-day precision of liraglutide was 3.5%-9.4% and 8.4%-9.8%, respectively, whereas its accuracy was between -12.6% and -1.3%. Intra- and inter-day precision of insulin degludec was 5.2%-13.6% and 11.8%-19.1%, respectively, showing an accuracy between -3.0% and 9.9%. As a result, the method was successfully applied to a pharmacokinetics study of liraglutide and insulin degludec following a single-dose subcutaneous administration to rats.
Asunto(s)
Cromatografía Liquida/métodos , Insulina de Acción Prolongada/sangre , Liraglutida/sangre , Espectrometría de Masas en Tándem/métodos , Animales , Estabilidad de Medicamentos , Insulina de Acción Prolongada/química , Insulina de Acción Prolongada/farmacocinética , Límite de Detección , Modelos Lineales , Liraglutida/química , Liraglutida/farmacocinética , Ratas , Reproducibilidad de los ResultadosRESUMEN
OBJECTIVE: This study aimed to explore the effects of ambient temperature and relative humidity on insulin pharmacodynamics in adults with type 1 diabetes. MATERIALS AND METHODS: A three-way, cross-over, randomised study was performed in adults with type 1 diabetes mellitus (n = 10). The pharmacodynamics profile of a single dose of short-acting insulin (insulin lispro) was investigated, using a controlled environmental chamber, under three environmental conditions: (a) temperature: 15°C and humidity: 10%; (b) temperature: 30°C and humidity: 10%; and (c) temperature: 30°C and humidity: 60%. A euglycaemic glucose clamp technique ensured constant blood glucose of 100 mg/dL (5.5 mmol/L). The following pharmacodynamic endpoints were calculated: maximum glucose infusion rate (GIRmax ), time to GIRmax (tGIRmax ), total area under the curve (AUC) for GIR from 0-6 hours (AUCGIR.0-6h ), and partial AUCs (AUCGIR.0-1h , AUCGIR.0-2h and AUCGIR.2-6h ). RESULTS: Higher temperature (30°C) under 10% fixed humidity conditions resulted in greater GIRmax (P = 0.04) and a later tGIR.max (P = 0.049) compared to lower temperature (15°C). Humidity did not affect any pharmacodynamic parameter. When the combined effects of temperature and humidity were explored, tGIR.max (P = 0.008) occurred earlier, with a lower late insulin pharmacodynamic effect (AUCGIR.2-6h ; P = 0.017) at a temperature of 15°C and humidity of 10% compared to a temperature of 30°C and humidity of 60%. CONCLUSIONS: High ambient temperature resulted in a greater insulin peak effect compared to low ambient temperature, with the contribution of high relative humidity apparent only at high ambient temperature. This suggests that patients with type 1 diabetes mellitus who are entering higher environmental temperatures, with or without high humidity, could experience more hypoglycaemic events.
Asunto(s)
Diabetes Mellitus Tipo 1/tratamiento farmacológico , Diabetes Mellitus Tipo 1/metabolismo , Ambiente , Humedad , Insulina/farmacocinética , Temperatura , Adolescente , Adulto , Área Bajo la Curva , Glucemia/efectos de los fármacos , Glucemia/metabolismo , Estudios Cruzados , Método Doble Ciego , Femenino , Humanos , Hipoglucemiantes/administración & dosificación , Hipoglucemiantes/sangre , Hipoglucemiantes/farmacocinética , Insulina/administración & dosificación , Insulina/sangre , Insulina Lispro/administración & dosificación , Insulina Lispro/sangre , Insulina Lispro/farmacocinética , Insulina de Acción Prolongada/administración & dosificación , Insulina de Acción Prolongada/sangre , Insulina de Acción Prolongada/farmacocinética , Masculino , Persona de Mediana Edad , Adulto JovenAsunto(s)
Diabetes Mellitus/tratamiento farmacológico , Composición de Medicamentos , Hipoglucemiantes/uso terapéutico , Insulina Glargina/uso terapéutico , Insulina Lispro/uso terapéutico , Insulina de Acción Prolongada/uso terapéutico , Insulina Regular Humana/farmacocinética , Diabetes Mellitus/sangre , Esquema de Medicación , Excipientes/química , Humanos , Hipoglucemiantes/administración & dosificación , Hipoglucemiantes/sangre , Hipoglucemiantes/farmacocinética , Inyecciones Subcutáneas , Insulina Glargina/administración & dosificación , Insulina Glargina/sangre , Insulina Glargina/farmacocinética , Insulina Lispro/administración & dosificación , Insulina Lispro/sangre , Insulina Lispro/farmacocinética , Insulina de Acción Prolongada/administración & dosificación , Insulina de Acción Prolongada/sangre , Insulina de Acción Prolongada/farmacocinética , Insulina Regular Humana/administración & dosificación , Insulina Regular Humana/sangre , Insulina Regular Humana/uso terapéutico , Concentración Osmolar , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/sangre , Proteínas Recombinantes/farmacocinética , Proteínas Recombinantes/uso terapéuticoRESUMEN
INTRODUCTION: To lower the barrier for initiating insulin treatment and obtain adequate glycemic control in type 2 diabetes mellitus (T2DM), new basal insulin preparations with improved pharmacological properties and consequently a lower risk of hypoglycemia are needed. The objective of this trial was to confirm the efficacy and compare the safety of insulin degludec (IDeg) with insulin glargine (IGlar) in a multinational setting with two thirds of subjects enrolled in China. METHODS: This was a 26-week, randomized, open-label, parallel-group, treat-to-target, non-inferiority trial in 833 subjects with T2DM (48 % were female, mean age 56 years, diabetes duration 8 years), inadequately controlled on oral antidiabetic drugs (OADs). Subjects were randomized 2:1 to once-daily IDeg (555 subjects) or IGlar (278 subjects), both with metformin. The primary endpoint was the change from baseline in glycosylated hemoglobin (HbA1c) after 26 weeks. RESULTS: The completion rate was high (IDeg 94.2 %; IGlar 91.4 %). Mean HbA1c decreased from 8.3 to 7.0 % in both groups. Estimated treatment difference (ETD) [95 % confidence interval (CI)] IDeg-IGlar in change from baseline was -0.05 % points [-0.18 to 0.08], confirming the non-inferiority of IDeg to IGlar. The proportion of subjects achieving HbA1c <7.0 % was 54.2 and 51.4 % with IDeg and IGlar, respectively (estimated odds ratio [95 % CI] IDeg/IGlar: 1.14 [0.84 to 1.54]). The mean decrease in fasting plasma glucose, self-measured plasma glucose profiles, and insulin dose were similar between groups. Numerically lower rates of overall (estimated rate ratio [95 % CI] IDeg/IGlar: 0.80 [0.59 to 1.10]) and nocturnal (0.77 [0.43 to 1.37]) confirmed hypoglycemia were observed with IDeg compared with IGlar. No treatment differences in other safety parameters were found. Subjects were more satisfied with the IDeg device compared with the IGlar device as reflected by the total Treatment Related Impact Measures-Diabetes Device score (ETD [95 % CI] IDeg-IGlar: 2.2 [0.2 to 4.3]). CONCLUSION: IDeg provided adequate glycemic control non-inferior to IGlar and a tendency for a lower hypoglycemia rate. IDeg is considered suitable for initiating insulin therapy in T2DM patients on OADs requiring intensified treatment. TRIAL REGISTRATION: Clinicaltrials.gov NCT01849289.
Asunto(s)
Diabetes Mellitus Tipo 2/tratamiento farmacológico , Hipoglucemiantes/uso terapéutico , Insulina Glargina/uso terapéutico , Insulina de Acción Prolongada/uso terapéutico , Glucemia/efectos de los fármacos , China , Femenino , Hemoglobina Glucada/efectos de los fármacos , Humanos , Hipoglucemia/fisiopatología , Hipoglucemiantes/administración & dosificación , Hipoglucemiantes/efectos adversos , Hipoglucemiantes/sangre , Insulina , Insulina Glargina/administración & dosificación , Insulina Glargina/efectos adversos , Insulina Glargina/sangre , Insulina de Acción Prolongada/administración & dosificación , Insulina de Acción Prolongada/efectos adversos , Insulina de Acción Prolongada/sangre , Masculino , Metformina/uso terapéutico , Persona de Mediana Edad , Resultado del TratamientoRESUMEN
Hypoalbuminemia is a well-known predictor of morbidity and mortality in cardiac surgery. Our aim was to establish the impact of serum albumin on outcomes after left ventricular assist device (LVAD) implantation. This was a single-institution retrospective review, including all patients who underwent LVAD implantation between March 2006 and June 2014. Two hundred patients were included in the analysis. Mean serum albumin was 3.27 ± 0.47 g/dl, with 7% in the low albumin group (<2.5 mg/dl), 67.5% in the mid-range (2.5-3.5 mg/dl), and 25.5% in the normal albumin groups (> 3.5 mg/dl). Lower albumin was associated with a significant increase in postoperative renal failure (42.9 vs. 16.5 vs. 17.3%; p = 0.05) and prolonged hospitalization (median 28.5 vs. 16 vs. 15.5 days; p = 0.008). Six month, 1 year, and 5 year survival was 79%, 79%, and 49% with low, 84%, 78%, and 51% with mid-range, and 94%, 88%, and 60% with normal albumin, respectively (p = 0.22). Preoperative hypoalbuminemia is associated with postoperative acute renal failure (ARF) and prolonged hospitalization after LVAD implantation, with no effect on overall survival. Hypoalbuminemia is most likely a marker of advanced disease and should not, in itself, be considered a contraindication to LVAD candidacy.
Asunto(s)
Corazón Auxiliar , Insulina de Acción Prolongada/sangre , Insulina Regular Humana/sangre , Adolescente , Adulto , Anciano , Femenino , Insuficiencia Cardíaca/sangre , Insuficiencia Cardíaca/cirugía , Humanos , Hipoalbuminemia/sangre , Masculino , Persona de Mediana Edad , Periodo Preoperatorio , Estudios Retrospectivos , Albúmina Sérica , Albúmina Sérica Humana , Resultado del Tratamiento , Adulto JovenRESUMEN
BACKGROUND: Management of diabetes in elderly patients is complicated by the elevated risk of insulin-induced hypoglycaemia. This is the first study to report the pharmacodynamic and pharmacokinetic characteristics of IDegAsp (insulin degludec [IDeg]/insulin aspart [IAsp]), a soluble co-formulation of a long-acting basal insulin analogue (IDeg) and a rapid-acting insulin analogue (IAsp) in a single injection, in elderly and younger adult subjects with type 1 diabetes using a glucose clamp. METHODS: In this randomised, single-centre, double-blind, single-dose (SD), two-period, crossover trial, 15 elderly subjects (aged ≥ 65 years) and 13 younger adults (aged 18-35 years) with type 1 diabetes were randomly assigned to two SD administrations of 0.5 U/kg IDegAsp or biphasic insulin aspart 30 (control) followed by a 26-h euglycaemic glucose clamp and 120-h pharmacokinetic blood sampling. The glucose infusion rate (GIR) profiles were extrapolated to simulated steady-state (SS) conditions using pharmacodynamic models. RESULTS: IDegAsp GIR profiles showed a distinct peak and rapid onset of action from IAsp followed by a separate and flat basal action from IDeg. Mean 24-h area under the GIR curve was similar in elderly subjects vs. younger adults (mean ratio 1.01 [95% confidence interval 0.69-1.47]). Simulated SS pharmacodynamic profiles with once-daily IDegAsp showed a parallel upshift in GIR profiles vs. SD profiles. The shape of the IDegAsp pharmacodynamic profile was retained with twice-daily dosing under simulated SS conditions. IDegAsp was well tolerated. CONCLUSIONS: The distinct prandial and basal pharmacodynamics of IDegAsp observed in younger adults were preserved in elderly subjects with type 1 diabetes. The glucose-lowering effect of IDegAsp was similar in elderly subjects and younger adults with type 1 diabetes.
Asunto(s)
Diabetes Mellitus Tipo 1/tratamiento farmacológico , Insulina de Acción Prolongada/uso terapéutico , Adulto , Factores de Edad , Anciano , Estudios Cruzados , Diabetes Mellitus Tipo 1/sangre , Manejo de la Enfermedad , Método Doble Ciego , Combinación de Medicamentos , Femenino , Técnica de Clampeo de la Glucosa , Humanos , Hipoglucemiantes/sangre , Hipoglucemiantes/uso terapéutico , Insulina de Acción Prolongada/sangre , Insulina de Acción Prolongada/farmacocinética , Masculino , Persona de Mediana Edad , Periodo Posprandial , Adulto JovenRESUMEN
Insulin degludec/liraglutide (IDegLira) is a novel fixed-ratio combination of the basal insulin insulin degludec (IDeg) and liraglutide, a glucagon-like peptide-1 analog. The pharmacokinetics (PK) and pharmacodynamics of IDegLira were assessed versus its components. A single-dose, randomized, 4-period crossover clinical pharmacology study in healthy subjects compared the bioavailability of IDegLira with its monocomponents. Dose proportionality, covariate effects on exposure, and exposure-response for change in glycated hemoglobin were analyzed based on data from a randomized treat-to-target phase 3 study in subjects with type 2 diabetes. Overall, the PK properties of IDeg and liraglutide were preserved for IDegLira. Liraglutide exposure was lower when dosed as IDegLira but met the criterion for equivalence. No relevant deviations from dose proportionality for the IDegLira components were observed. Covariate effects on exposure were consistent with previous results. Glycemic response to IDegLira was larger than with IDeg or liraglutide alone, reflecting their distinct glucose-lowering effects throughout the dose/exposure range.
Asunto(s)
Glucemia/efectos de los fármacos , Diabetes Mellitus Tipo 2/sangre , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Hipoglucemiantes/administración & dosificación , Hipoglucemiantes/farmacocinética , Insulina de Acción Prolongada/farmacología , Insulina de Acción Prolongada/farmacocinética , Liraglutida/farmacología , Liraglutida/farmacocinética , Adolescente , Adulto , Relación Dosis-Respuesta a Droga , Combinación de Medicamentos , Femenino , Hemoglobina Glucada/efectos de los fármacos , Humanos , Hipoglucemiantes/sangre , Hipoglucemiantes/farmacología , Insulina de Acción Prolongada/administración & dosificación , Insulina de Acción Prolongada/sangre , Insulina de Acción Prolongada/uso terapéutico , Liraglutida/administración & dosificación , Liraglutida/sangre , Liraglutida/uso terapéutico , Masculino , Persona de Mediana Edad , Adulto JovenRESUMEN
BACKGROUND/AIMS: Effects of preoperative one week enteral nutrition (EN) support on the postoperative nutritional status, immune function and inflammatory response of gastric cancer patients were investigated. MATERIALS AND METHODS: 106 cases of gastric cancer patients were randomly divided into preoperative one week EN group (trial group) and early postoperative EN group (control group), which were continuously treated with EN support until the postoperative 9th day according to different treatment protocols. All the patients were checked for their body weight, skinfold thickness, upper arm circumference, white blood cell count (WBC), albumin (ALB), prealbumin (PA), C-reactive protein (CRP), humoral immunity (IgA, IgG), T cell subsets (CD4, CD8 and CD4/CD8), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), etc. on the preoperative and the postoperative 1st and 10th day, respectively. RESULTS: PA and IgG levels of the experimental group were higher than those of the control group on the postoperative 10th day, whereas IL-6 level of the experimental group was lower than that of the control group. CONCLUSION: EN support for preoperative gastric cancer patients will improve the postoperative nutritional status and immune function, alleviate inflammatory response, and facilitate the recovery of patients.
Asunto(s)
Biomarcadores/sangre , Nutrición Enteral/métodos , Estado Nutricional/efectos de los fármacos , Periodo Posoperatorio , Periodo Preoperatorio , Neoplasias Gástricas/terapia , Adulto , Anciano , Peso Corporal/efectos de los fármacos , Proteína C-Reactiva/análisis , Recuento de Linfocito CD4 , Linfocitos T CD8-positivos , Femenino , Humanos , Inmunidad Humoral/efectos de los fármacos , Inmunoglobulina A/sangre , Inmunoglobulina G/sangre , Insulina de Acción Prolongada/sangre , Insulina Regular Humana/sangre , Interleucina-6/sangre , Recuento de Leucocitos , Masculino , Persona de Mediana Edad , Prealbúmina/análisis , Albúmina Sérica , Albúmina Sérica Humana , Grosor de los Pliegues Cutáneos , Neoplasias Gástricas/inmunología , Neoplasias Gástricas/fisiopatología , Neoplasias Gástricas/cirugía , Subgrupos de Linfocitos T/citología , Resultado del Tratamiento , Factor de Necrosis Tumoral alfa/sangreRESUMEN
BACKGROUND: Patients with type 1 diabetes face heightened risk of hypoglycemia after exercise. Subsequent overfeeding, as a preventative measure against hypoglycemia, negates the energy deficit after exercise. Patients are also required to reduce the insulin dose administered with postexercise foods to further combat hypoglycemia. However, the insulin dose is dictated solely by the carbohydrate content, even though postprandial glycemia is vastly influenced by glycemic index (GI). With a need to control the postexercise energy balance, appetite responses after meals differing in GI are of particular interest. OBJECTIVES: We assessed the appetite response to low-glycemic index (LGI) and high-glycemic index (HGI) postexercise meals in type 1 diabetes patients. This assessment also offered us the opportunity to evaluate the influence of GI on appetite responses independently of insulinemia, which confounds findings in individuals without diabetes. DESIGN: Ten physically active men with type 1 diabetes completed 2 trials in a randomized crossover design. After 45 min of treadmill exercise at 70% of the peak oxygen uptake, participants consumed an LGI (GI â¼37) or HGI (GI â¼92) meal with a matched macronutrient composition, negligible fiber content, and standardized insulin-dose administration. The postprandial appetite response was determined for 180 min postmeal. During this time, circulating glucose, insulin, glucagon, and glucagon-like peptide-1 (GLP-1) concentrations and subjective appetite ratings were determined. RESULTS: The HGI meal produced an â¼60% greater postprandial glucose area under the curve (AUC) than did the LGI meal (P = 0.008). Insulin, glucagon, and GLP-1 did not significantly differ between trials (P > 0.05). The fullness AUC was â¼25% greater after the HGI meal than after the LGI meal (P < 0.001), whereas hunger sensations were â¼9% lower after the HGI meal than after the LGI meal (P = 0.001). CONCLUSION: Under conditions of matched insulinemia and fiber, an HGI postexercise meal suppresses feelings of hunger and augments postprandial fullness sensations more so than an otherwise equivalent LGI meal in type 1 diabetes patients.
Asunto(s)
Regulación del Apetito , Diabetes Mellitus Tipo 1/dietoterapia , Dieta para Diabéticos , Ejercicio Físico , Índice Glucémico , Comidas , Adulto , Regulación del Apetito/efectos de los fármacos , Terapia Combinada , Estudios Cruzados , Diabetes Mellitus Tipo 1/sangre , Diabetes Mellitus Tipo 1/tratamiento farmacológico , Diabetes Mellitus Tipo 1/terapia , Fibras de la Dieta/administración & dosificación , Quimioterapia Combinada , Glucagón/sangre , Péptido 1 Similar al Glucagón/sangre , Humanos , Hiperglucemia/prevención & control , Hipoglucemia/prevención & control , Hipoglucemiantes/sangre , Hipoglucemiantes/farmacocinética , Hipoglucemiantes/uso terapéutico , Insulina Aspart/sangre , Insulina Aspart/farmacocinética , Insulina Aspart/uso terapéutico , Insulina Glargina , Insulina de Acción Prolongada/sangre , Insulina de Acción Prolongada/farmacocinética , Insulina de Acción Prolongada/uso terapéutico , Trote , Masculino , Periodo PosprandialRESUMEN
AIMS: To characterize the variability in exposure and metabolic effect of insulin glargine 300 U/ml (Gla-300) at steady state in people with type 1 diabetes (T1DM). METHODS: A total of 50 participants with T1DM underwent two 24-h euglycaemic clamps in steady-state conditions after six once-daily administrations of 0.4 U/kg Gla-300 in a double-blind, randomized, two-treatment, two-period, crossover clamp study. Participants were randomized to receive Gla-300 as a standard cartridge formulation in the first treatment period, and as a formulation with enhanced stability through polysorbate-20 addition in the second treatment period, or vice versa. This design allowed the assessment of bioequivalence between formulations and, subsequently, within- and between-day variability. RESULTS: The cumulative exposure and effect of Gla-300 developed linearly over 24 h, and were evenly distributed across 6- and 12-h intervals. Diurnal fluctuation in exposure (within-day variability) was low; the peak-to-trough ratio of insulin concentration profiles was <2, and both the swing and peak-to-trough fluctuation were <1. Day-to-day reproducibility of exposure was high: the between-day within-subject coefficients of variation for total systemic exposure (area under the serum insulin glargine concentration time curve from time 0 to 24 h after dosing) and maximum insulin concentration were 17.4% [95% confidence interval (CI) 15-21] and 33.4% (95% CI 28-41), respectively. Reproducibility of the metabolic effect was lower than that of exposure. CONCLUSIONS: Gla-300 provides predictable, evenly distributed 24-h coverage as a result of low fluctuation and high reproducibility in insulin exposure, and appears suitable for effective basal insulin use.
Asunto(s)
Glucemia/efectos de los fármacos , Diabetes Mellitus Tipo 1/tratamiento farmacológico , Hipoglucemiantes/administración & dosificación , Insulina de Acción Prolongada/administración & dosificación , Adolescente , Adulto , Glucemia/metabolismo , Estudios Cruzados , Diabetes Mellitus Tipo 1/sangre , Método Doble Ciego , Esquema de Medicación , Femenino , Técnica de Clampeo de la Glucosa/métodos , Humanos , Hipoglucemiantes/sangre , Hipoglucemiantes/farmacocinética , Insulina Glargina , Insulina de Acción Prolongada/sangre , Insulina de Acción Prolongada/farmacocinética , Masculino , Persona de Mediana Edad , Reproducibilidad de los Resultados , Equivalencia Terapéutica , Adulto JovenRESUMEN
BACKGROUND: A direct comparison of radioimmunoassay (RIA) and LC-MS/MS for insulin glargine quantification in human plasma is provided. RESULTS: Compared with the RIA, the LC-MS/MS assay exhibited comparable/improved sensitivity (LLOQ at 0.1 ng/ml [Ë16.7 pM or 2.8 µU/ml] for glargine and its metabolites M1 and M2, respectively) and ruggedness. Most importantly, it demonstrated a superior specificity advantage against the interference from endogenous insulin, exogenous insulin analogs (e.g., Novolog(®), Humalog(®) or Levemir(®), routine treatment for diabetes mellitus) and potentially pre-existing anti-insulin antibodies in patient samples. The data obtained from diabetic patients suggested the LC-MS/MS assay substantially improved pharmacokinetic characterization of glargine. CONCLUSION: LC-MS/MS overcame common limitations of RIA, and provided critically needed specificity to support glargine clinical development, without sacrificing assay sensitivity and ruggedness.
Asunto(s)
Descubrimiento de Drogas , Insulina de Acción Prolongada/sangre , Insulina de Acción Prolongada/farmacocinética , Radioinmunoensayo/métodos , Espectrometría de Masas en Tándem , Secuencia de Aminoácidos , Artefactos , Autoanticuerpos/sangre , Autoanticuerpos/inmunología , Cromatografía Liquida , Humanos , Insulina Glargina , Insulina de Acción Prolongada/química , Insulina de Acción Prolongada/inmunología , Datos de Secuencia MolecularRESUMEN
AIMS: To determine the influence of different volumes of resistance exercise on circulating interleukin-6 (IL-6) and to explore the relationships between IL-6 and glycaemia. METHODS: Eight participants with complication-free type 1 diabetes, whose mean ± SEM age was 38 (6) years, mean ± SEM HbA(1c) concentration was 71 ±11 mmol/mol (8.7 ±1.0%) and mean ± SEM type 1 diabetes duration was 15 ±13 years, attended the research facility after an overnight fast on four separate occasions, having administered their basal insulin the night before (glargine 27.5±3.1U, n=8), but omitted morning rapid-acting insulin. Participants completed either a one-set (14-min), two-set (28-min), or three-set (42-min) resistance exercise trial (eight exercises × 10 repetitions) at 67±3% one-repetition maximum followed by a 60-min recovery, or a resting control trial. Venous blood samples were taken before and after exercise. Data were analysed using repeated-measures ANOVA (P≤0.05). RESULTS: Whereas IL-6 levels remained similar to baseline levels after one set of resistance exercises (30 min, P=0.287; 60 min, P=0.318), IL-6 levels were > baseline levels at 60 min post-exercise after a two-set exercise trial (2.94 ± 0.94 pg/ml, P=0.002) and doubled at both 30 min (4.01 ± 1.00 pg/ml, P=0.048) and 60 min (4.28 ± 1.25 pg/ml, P=0.084) post-exercise after the three-set resistance exercise trial. Post-exercise blood glucose area under the curve (mmol/l/60 min) was greater after both the one-set (P=0.025) and two-set trials (P=0.008), than after the control trial, but similar between the three-set trial and the control trial (P=0.240). The rise in IL-6 from baseline to peak concentration significantly correlated inversely with blood glucose area under the curve (r=-0.65, P=0.041). CONCLUSIONS: Circulating IL-6 is increased by resistance exercise in a volume-dependent manner, and resistance exercise-induced increases in IL-6 correlated with reductions in post-exercise hyperglycaemia in type 1 diabetes, suggesting a role for IL-6 in improving post-resistance exercise glycaemic disturbances in type 1 diabetes.
Asunto(s)
Diabetes Mellitus Tipo 1/terapia , Hiperglucemia/prevención & control , Interleucina-6/sangre , Músculo Esquelético/metabolismo , Entrenamiento de Fuerza , Regulación hacia Arriba , Adulto , Glucemia/análisis , Estudios de Cohortes , Terapia Combinada , Diabetes Mellitus Tipo 1/sangre , Diabetes Mellitus Tipo 1/tratamiento farmacológico , Diabetes Mellitus Tipo 1/metabolismo , Dieta para Diabéticos , Femenino , Hemoglobina Glucada/análisis , Humanos , Hipoglucemiantes/sangre , Hipoglucemiantes/farmacocinética , Hipoglucemiantes/uso terapéutico , Insulina Glargina , Insulina de Acción Prolongada/sangre , Insulina de Acción Prolongada/farmacocinética , Insulina de Acción Prolongada/uso terapéutico , Masculino , Estudios Retrospectivos , Factores de TiempoRESUMEN
BACKGROUND AND AIMS: After subcutaneous injection insulin glargine is rapidly metabolized to M1 and M2. In vitro, both M1 and M2 have metabolic effects and bind to IGF-1R similarly to human insulin, whereas glargine exhibits a higher affinity for the IGF-1R and greater mitogenetic effects. The present study was specifically designed to establish the dose-response metabolism of glargine over 24 h following s.c. injection in T2DM subjects on long-term use of glargine. METHODS AND RESULTS: Ten subjects with T2DM were studied during 24 h after s.c. injection of 0.4 (therapeutic) and 0.8 (high dose) U/kg of glargine on two separate occasions during euglycaemic clamps (cross-over design). Glargine, M1 and M2 over 24 h period were determined in appropriately processed plasma samples by a specific liquid chromatography-tandem mass spectrometry assay. Plasma M1 concentration (AUC0-24 h) was detected in all subjects and increased by increasing the glargine dose from therapeutic to high dose (p = 0.008). Glargine was detectable in 6 (therapeutic dose) and 9 (high dose) out of the 10 subjects and also increased by increasing the dose (p = 0.031). However, glargine concentration (AUC0-24 h--high dose) represented at most only 9.7% (4.6-15%) of the total amount of insulin measured in the blood. M2 was not detected at all. CONCLUSION: In T2DM people on long-term use of insulin glargine, even with higher doses (0.8 U/kg), glargine is nearly totally metabolized to the active metabolite M1. Glargine is often detectable in plasma, but its concentration remains well below that needed in vitro to potentiate IGF-1R binding and mitogenesis.
Asunto(s)
Diabetes Mellitus Tipo 2/tratamiento farmacológico , Hipoglucemiantes/sangre , Hipoglucemiantes/farmacología , Insulina de Acción Prolongada/sangre , Insulina de Acción Prolongada/farmacología , Anciano , Glucemia/metabolismo , Cromatografía Liquida , Estudios Cruzados , Diabetes Mellitus Tipo 2/sangre , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Determinación de Punto Final , Glucagón/sangre , Técnica de Clampeo de la Glucosa , Índice Glucémico , Humanos , Inyecciones Subcutáneas , Insulina Glargina , Persona de Mediana Edad , Espectrometría de Masas en TándemRESUMEN
We have previously shown that insulin plays an important role in the nutrient-induced insulin resistance. In this study, we tested the hypothesis that chronic exposure to excess long-acting insulin (glargine) can cause typical type 2 diabetes mellitus (T2DM) in normal mice fed on a chow diet. C57BL/6 mice were treated with glargine once a day for 8 weeks, followed by evaluations of food intake, body weight, blood levels of glucose, insulin, lipids, and cytokines, insulin signaling, histology of pancreas, ectopic fat accumulation, oxidative stress level, and cholesterol content in mitochondria in tissues. Cholesterol content in mitochondria and its association with oxidative stress in cultured hepatocytes and ß-cells were also examined. Results show that chronic exposure to glargine caused insulin resistance, hyperinsulinemia, and relative insulin deficiency (T2DM). Treatment with excess glargine led to loss of pancreatic islets, ectopic fat accumulation in liver, oxidative stress in liver and pancreas, and increased cholesterol content in mitochondria of liver and pancreas. Prolonged exposure of cultured primary hepatocytes and HIT-TI5 ß-cells to insulin induced oxidative stress in a cholesterol synthesis-dependent manner. Together, our results show that chronic exposure to excess insulin can induce typical T2DM in normal mice fed on a chow diet.
Asunto(s)
Diabetes Mellitus Tipo 2/fisiopatología , Dieta , Resistencia a la Insulina/fisiología , Insulina de Acción Prolongada/administración & dosificación , Animales , Glucemia/metabolismo , Peso Corporal/efectos de los fármacos , Peso Corporal/fisiología , Línea Celular Tumoral , Células Cultivadas , Colesterol/metabolismo , Cricetinae , Citocinas/sangre , Diabetes Mellitus Tipo 2/sangre , Diabetes Mellitus Tipo 2/inducido químicamente , Grasas/metabolismo , Hepatocitos/efectos de los fármacos , Hepatocitos/metabolismo , Hipoglucemiantes/administración & dosificación , Hipoglucemiantes/toxicidad , Insulina Glargina , Insulina de Acción Prolongada/sangre , Insulina de Acción Prolongada/toxicidad , Insulinoma/metabolismo , Insulinoma/patología , Lípidos/sangre , Lipogénesis/efectos de los fármacos , Lipogénesis/genética , Hígado/efectos de los fármacos , Hígado/metabolismo , Masculino , Ratones , Ratones Endogámicos C57BL , Estrés Oxidativo/efectos de los fármacos , Páncreas/efectos de los fármacos , Páncreas/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa InversaRESUMEN
LY2605541 is a novel basal insulin analog with a prolonged duration of action. Two Phase I studies assessed LY2605541 pharmacokinetics (PK), glucodynamics (GD), and tolerability in healthy subjects. In Study 1, 33 subjects received single subcutaneous (SC) doses of LY2605541 (0.01-2.22 U/kg) and insulin glargine (0.5-0.8 U/kg) followed by euglycemic clamp for up to 24-36 hours. In Study 2, absolute bioavailability of SC LY2605541 was assessed in 8 subjects by comparing dose normalized area under concentration versus time curve of SC against IV administration. Time-to-maximum plasma concentration (medians) and geometric means for half-life (t½ ) and apparent clearance, respectively, ranged from 18.0 to 42.0 hours, 24.4-45.5 hours, and 1.8-2.8 L/h for SC LY2605541, versus 10.0-12.0 hours, 12.2-14.9 hours, and 51.4-65.2 L/h for SC insulin glargine. LY2605541 glucose infusion rate (GIR) profiles were sustained for ≥36 hours versus glargine GIR profiles, which waned at 24 hours. After IV administration, LY2605541's geometric mean t½ was 2.3 hours. LY2605541 intra-subject variability (CV%) was <18% for PK and <32% for GD parameters. The most common adverse events were related to study procedures and were mild-moderate in severity. These results established a well-tolerated baseline dose for LY2605541 with a relatively flat PK profile and low intra-subject variability.
Asunto(s)
Glucemia/análisis , Drogas en Investigación/farmacocinética , Hipoglucemiantes/farmacocinética , Insulina Lispro/farmacocinética , Polietilenglicoles/farmacocinética , Adulto , Disponibilidad Biológica , Estudios de Cohortes , Estudios Cruzados , Relación Dosis-Respuesta a Droga , Drogas en Investigación/administración & dosificación , Drogas en Investigación/efectos adversos , Drogas en Investigación/análisis , Femenino , Técnica de Clampeo de la Glucosa , Semivida , Humanos , Hipoglucemiantes/administración & dosificación , Hipoglucemiantes/efectos adversos , Hipoglucemiantes/sangre , Infusiones Intravenosas , Inyecciones Subcutáneas , Insulina Glargina , Insulina Lispro/administración & dosificación , Insulina Lispro/efectos adversos , Insulina Lispro/sangre , Insulina de Acción Prolongada/administración & dosificación , Insulina de Acción Prolongada/efectos adversos , Insulina de Acción Prolongada/sangre , Insulina de Acción Prolongada/farmacocinética , Masculino , Tasa de Depuración Metabólica , Persona de Mediana Edad , Polietilenglicoles/administración & dosificación , Polietilenglicoles/efectos adversos , Reproducibilidad de los Resultados , Adulto JovenRESUMEN
BACKGROUND: Insulin degludec is a new-generation basal insulin with an ultra-long duration of action. We evaluated the pharmacokinetic properties of insulin degludec in subjects with normal renal function; mild, moderate or severe renal impairment; or end-stage renal disease (ESRD) undergoing hemodialysis. METHODS: Thirty subjects (n = 6 per group) received a single subcutaneous dose of 0.4 U/kg insulin degludec. Blood samples up to 120 h post-dose and fractionated urine samples were collected. RESULTS: The ultra-long pharmacokinetic properties of insulin degludec were preserved in subjects with renal impairment, with no statistically significant differences in absorption or clearance, compared with subjects with normal renal function. In subjects with ESRD, pharmacokinetic parameters were similar whether the insulin degludec pharmacokinetic assessment period included hemodialysis or not, and total exposure was comparable to subjects with normal renal function. Simulated mean steady-state pharmacokinetic profiles were comparable between groups. CONCLUSION: This study indicated dose adjustments due to impaired renal function should not be required for insulin degludec.
Asunto(s)
Hipoglucemiantes/farmacocinética , Insulina de Acción Prolongada/farmacocinética , Insuficiencia Renal/metabolismo , Anciano , Diabetes Mellitus Tipo 2/metabolismo , Soluciones para Diálisis/análisis , Femenino , Humanos , Hipoglucemiantes/sangre , Hipoglucemiantes/orina , Insulina de Acción Prolongada/sangre , Insulina de Acción Prolongada/orina , Riñón/metabolismo , Masculino , Persona de Mediana Edad , Diálisis RenalRESUMEN
BACKGROUND: The aim of this study was to investigate the incidence, etiology, clinical outcomes, and prognosis of nonthyroidal illness syndrome (NTIS) in patients with enterocutaneous fistulas. METHODS: We prospectively collected 226 patients with enterocutaneous fistulas. Demographics, Acute Physiology and Chronic Health Evaluation II (APACHE II) and Sequential Organ Failure Assessment scores, C-reactive protein, body mass index, albumin, and thyroidal hormones were evaluated for each patient. RESULTS: The incidence of NTIS was 57.5% in patients with enterocutaneous fistulas. Age and the APACHE II and Sequential Organ Failure Assessment scores were significantly higher, whereas albumin was lower in the NTIS group compared with those in the euthyroid group. A decreased sum activity of deiodinases and a reduced ratio of total thyroxin/free thyroxin and total triiodothyronine/free triiodothyronine were observed in the NTIS group. Patients with NTIS suffered longer durations in the intensive care unit and higher possibilities of mechanical ventilation. The cumulative survival rate was significantly lower in the NTIS group. CONCLUSIONS: NTIS was common, and patients with NTIS displayed worse clinical outcome and prognosis. A hypodeiodination condition and a potential thyroid hormone-binding dysfunction may play a role in the etiology of NTIS. A low serum albumin concentration and a high APACHE II score were risk factors of NTIS in enterocutaneous fistulas.
Asunto(s)
Fístula Cutánea/complicaciones , Síndromes del Eutiroideo Enfermo/etiología , Fístula Intestinal/complicaciones , APACHE , Adulto , Índice de Masa Corporal , Proteína C-Reactiva/metabolismo , Distribución de Chi-Cuadrado , Demografía , Síndromes del Eutiroideo Enfermo/epidemiología , Síndromes del Eutiroideo Enfermo/fisiopatología , Femenino , Humanos , Incidencia , Insulina de Acción Prolongada/sangre , Insulina Regular Humana/sangre , Masculino , Persona de Mediana Edad , Insuficiencia Multiorgánica/fisiopatología , Pronóstico , Estudios Prospectivos , Análisis de Regresión , Factores de Riesgo , Albúmina Sérica , Albúmina Sérica Humana , Tasa de Supervivencia , Hormonas Tiroideas/sangreAsunto(s)
Diabetes Mellitus Tipo 1/tratamiento farmacológico , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Diabetes Mellitus Tipo 2/metabolismo , Hipoglucemiantes/administración & dosificación , Hipoglucemiantes/sangre , Insulina de Acción Prolongada/administración & dosificación , Insulina de Acción Prolongada/sangre , Insulina de Acción Prolongada/farmacocinética , Femenino , Humanos , Insulina Glargina , MasculinoRESUMEN
OBJECTIVE: In vivo, after subcutaneous injection, insulin glargine (21(A)-Gly-31(B)-Arg-32(B)-Arg-human insulin) is enzymatically processed into 21(A)-Gly-human insulin (metabolite 1 [M1]). 21(A)-Gly-des-30(B)-Thr-human insulin (metabolite 2 [M2]) is also found. In vitro, glargine exhibits slightly higher affinity, whereas M1 and M2 exhibit lower affinity for IGF-1 receptor, as well as mitogenic properties, versus human insulin. The aim of the study was to quantitate plasma concentrations of glargine, M1, and M2 after subcutaneous injection of glargine in male type 1 diabetic subjects. RESEARCH DESIGN AND METHODS: Glargine, M1, and M2 were determined in blood samples obtained from 12, 11, and 11 type 1 diabetic subjects who received single subcutaneous doses of 0.3, 0.6, or 1.2 units · kg(-1) glargine in a euglycemic clamp study. Glargine, M1, and M2 were extracted using immunoaffinity columns and quantified by a specific liquid chromatography-tandem mass spectrometry assay. Lower limit of quantification was 0.2 ng · mL(-1) (33 pmol · L(-1)) per analyte. RESULTS: Plasma M1 concentration increased with increasing dose; geometric mean (percent coefficient of variation) M1-area under the curve between time of dosing and 30 h after dosing (AUC(0-30h)) was 1,261 (66), 2,867 (35), and 4,693 (22) pmol · h · L(-1) at doses of 0.3, 0.6, and 1.2 units · kg(-1), respectively, and correlated with metabolic effect assessed as pharmacodynamics-AUC(0-30h) of the glucose infusion rate following glargine administration (r = 0.74; P < 0.01). Glargine and M2 were detectable in only one-third of subjects and at a few time points. CONCLUSIONS: After subcutaneous injection of glargine in male subjects with type 1 diabetes, exposure to glargine is marginal, if any, even at supratherapeutic doses. Glargine is rapidly and nearly completely processed to M1 (21(A)-Gly-human insulin), which mediates the metabolic effect of injected glargine.
Asunto(s)
Diabetes Mellitus Tipo 1/tratamiento farmacológico , Hipoglucemiantes/administración & dosificación , Hipoglucemiantes/sangre , Insulina de Acción Prolongada/administración & dosificación , Insulina de Acción Prolongada/sangre , Adulto , Diabetes Mellitus Tipo 1/sangre , Técnica de Clampeo de la Glucosa , Humanos , Hipoglucemiantes/metabolismo , Hipoglucemiantes/uso terapéutico , Inyecciones Subcutáneas , Insulina Glargina , Insulina de Acción Prolongada/metabolismo , Insulina de Acción Prolongada/uso terapéutico , Masculino , Persona de Mediana EdadRESUMEN
Two experiments were conducted to investigate effects of administering increasing doses of 2 different preparations of long-acting insulin on the 24-h profiles of plasma glucose and insulin concentrations in mid lactation dairy cows. The 2 separately analyzed experiments investigated the effects administering either Humulin N (H), a neutral protamine Hagedorn insulin, or insulin glargine (Lantus, L), an insulin analog, at doses of 0 (control), 0.1, 0.2, and 0.4 IU/kg of body weight in a randomized complete block design. Sixteen cows (237±11 d in milk for H; 213±10 d in milk for L; mean ± SD) were used for each insulin preparation, resulting in n=4 for each dose within insulin preparation. Cows were fitted with a single jugular catheter on the day before the study. On the day of the study, cows were given treatments by subcutaneous injection of either sterile water or the designated insulin type and dose. Blood samples were taken hourly from the jugular catheter. Subcutaneous injection of both H and L resulted in linear decreases in plasma glucose concentrations, increased area under the curve, and decreased nadir for plasma glucose following administration of the insulin preparations. Plasma insulin concentration linearly increased with increasing dose of H. Though elevated concentrations of insulin were measurable in cows treated with H, they were not measurable in cows treated with L. Attempts to measure overall insulin concentrations and metabolites of L by a commercially available ELISA and a commercially available RIA kit were not successful and did not retrieve values that we felt truly represented the amount of insulin activity exhibited during this treatment. Both long-acting insulin preparations elicited insulin-like activity in lactating dairy cows, as evidenced by reduced plasma glucose concentrations. Given these results, the potential exists to use both H and L to study the effects of insulin in mid lactation dairy cows without the confounding effect of severe hypoglycemia (<20 mg/dL) or concurrent provision of glucose during treatment.